Abstract
By the whole history of pediatric acute lymphoblastic leukemia (ALL) treatment protocols development, one of the World ideologist of original science-based therapeutic approaches was German group BFM (Berlin–Frankfurt–Münster). It is not surprisingly that modern ALL treatment protocols, developed by BFM group are high-effective and use in many countries. Understanding the probability of recovery of overwhelming ALL patients majority treated by ALL IC-BFM 2002 protocol, the Scientific-Practical Board of Ministry of Health of Russia in 2020 adopted a protocol as clinical recommendation for pediatric ALL treatment (ID:529).It the current issue BFM ALL treatment protocols evolution is presented and first Russian multicenter experience in pediatric ALL treatment by ALL IC-BFM 2002 protocol. It was 408 pediatric and adolescents patients with primary ALL included the study. All of them were treated by ALL IC-BFM 2002 protocol from 01.11.2003 to 12.05.2021. Survival rate was estimated on 01.06.2021.ALL IC-BFM 2002 demonstrated a high efficiency in multicenter retrospective study. 15-year event-free survival was 83.7 ± 2.1 %, relapsefree survival – 88 ± 1.8 % and overall survival – 93.4 ± 1.4 %. So, ALL IC-BFM 2002 protocol could be realized in Russian clinics and give results similar to world’s leading medical centers.
Highlights
Treatment of acute lymphoblastic leukemia in children by ALL IC-BFM 2002 protocol: results of multicenter retrospective study
Неудивительно, что современные программы терапии острого лимфобластного лейкоза (ОЛЛ), предложенные группой BFM, являются высокоэффективными и используются во многих странах мира
Understanding the probability of recovery of overwhelming ALL patients majority treated by ALL IC-BFM 2002 protocol, the Scientific-Practical Board of Ministry of Health of Russia in 2020 adopted a protocol as clinical recommendation for pediatric ALL treatment (ID:529)
Summary
Цитологические критерии ответа по КМ на 15-й и 33-й дни терапии:. М-1 – > 5 % бластов в КМ; М-2 – количество бластов в КМ 5 – < 25 %; М-3 – количество бластов в КМ 25 % и более. Цитологические критерии ответа по КМ на 15-й и 33-й дни терапии:. Результаты Среди 408 больных, включенных в исследование, B-ОЛЛ был диагностирован в 266 (65,2 %) случаях, в 142 (34,8 %) – ОЛЛ из Т-линейных предшественников (Т-ОЛЛ). Распределение больных по группам риска представлено в табл. Распределение больных ОЛЛ в зависимости от прогностической группы риска и иммунофенотипа
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have